Amplification grew by 20.6%, reflecting rising global demand for image intensifier tubes for defence night vision systems, with capacity expansion now expected to increase by 40% by 2027. Detection & Imaging rose by 26.2%, with strong momentum in defence imaging and protection technologies, especially for drone and counter-drone systems.
The company continued to pursue its bolt-on acquisition strategy, closing three transactions in 2025 to boost innovation and expand its defence-focused portfolio. Noxant (March), NVLS (July), and Phasics (October) have strengthened Exosens’ position in night vision, drone-based systems, and wave front sensing technologies.
Jérôme Cerisier, CEO of Exosens, said: “We are pleased to report our nine-month 2025 performance which shows sustained revenue and adjusted gross margin growth driven by strong defense tailwinds.” He added: “With a +23% year-over-year growth and the closing of the acquisitions of NVLS in July and Phasics in October, Exosens is pursuing its strategy to position itself as a differentiated technology platform in Photonics, focused on fast-growing niche markets in defense, life sciences, industrial control, and nuclear.”
Mr Cerisier noted the continued strength in defence applications and confirmed further investments in production capacity to meet demand. “In response to sustained demand, we have decided to implement an additional staggered capacity expansion, following the investment we announced in March, and we now expect to deliver a combined +40% increase in our global capacity by 2027,” he said.
The company also completed the divestment of its Microwave Amplification business to focus on higher-growth core areas. Restated financial figures for both 2024 and 2025 have been adjusted in accordance with IFRS 5.
Exosens confirmed it remains “fully on track to deliver on our financial guidance for the year”, expecting continued revenue growth in the high teens and adjusted EBITDA growth in the low twenties.
